v3.25.4
Segment Reporting (Details)
$ in Thousands
12 Months Ended
Dec. 31, 2025
USD ($)
segment
Dec. 31, 2024
USD ($)
Segment Reporting    
Number of reportable segments | segment 1  
Research and development    
Total research and development expenses $ 23,276 $ 40,179
General and administrative    
Total general and administrative expenses 19,875 24,988
Impairment of long-lived assets 6,145 5,233
Loss from operations 49,296 70,400
Other (income) expense, net (3,774) (5,633)
Net loss 45,522 64,767
Genetic Medicines Segment    
Research and development    
Wages, benefits, and other payroll 7,462 12,265
Third-party costs 14,532 22,691
Share-based compensation 842 2,529
Depreciation and amortization 440 2,694
Total research and development expenses 23,276 40,179
General and administrative    
Wages, benefits, and other payroll 7,784 9,255
Third-party costs 9,644 12,055
Share-based compensation 2,159 3,291
Depreciation and amortization 288 387
Total general and administrative expenses 19,875 24,988
Impairment of long-lived assets 6,145 5,233
Loss from operations 49,296 70,400
Other (income) expense, net (3,774) (5,633)
Net loss $ 45,522 $ 64,767